logo
Gabon longs to cash in on sacred hallucinogenic remedy

Gabon longs to cash in on sacred hallucinogenic remedy

France 2410-05-2025
For centuries, religious devotees have eaten it -- a psychotropic shrub that users say has addiction-fighting powers.
It fascinates foreign visitors, psychiatric patients and rich pharmaceutical companies that want to market it.
Now this central African country, where its use is enshrined in ancestral tradition, is scrambling to avoid missing out on the boom.
Teddy Van Bonda Ndong, 31, an initiate in the Bwiti spiritual tradition, calls it "sacred wood". He consumes it in small amounts daily, he said, for his "mental and physical health".
"It has a lot of power to help human beings," added Stephen Windsor-Clive, a 68-year-old retiree.
"It's untapped. A mysterious force lies within this plant."
He travelled to Gabon from Britain and consumed iboga -- in a powder ground from its roots -- during a 10-day Bwiti ceremony.
He tried it with a view to adopting it as a treatment for his daughter, who suffers from mental illness.
Economic potential
Given the interest, Gabon is seeking to channel the plant onto the international marketplace.
Exports of iboga products, including its active ingredient ibogaine, are few and strictly regulated in the country.
It grows mostly in the wild, but "more and more effort is being made to domesticate the plant", said Florence Minko, an official in the forestry ministry.
Potentially toxic in high doses, ibogaine can have effects similar to LSD, mescaline or amphetamines, and cause anxiety and hallucinations.
But users believe it can help drug addicts kick their habit and treat post-traumatic stress and neurological illnesses.
Yoan Mboussou, a local microbiologist and Bwiti initiate, hopes to gain an export licence for the 500-milligram ibogaine capsules he produces at his laboratory near the capital Libreville.
He sells them in Gabon as a food supplement, declaring them to have "anti-fatigue, antioxidant and anti-addictive" qualities.
Iboga, he believes, "is a potential lever to develop the economy and the whole country".
Tradition and IP
Countries such as the United States and France class iboga as a narcotic because of health risks identified in studies, especially heart issues. But it is used in treatment centres in countries including the Netherlands, Mexico and Portugal.
Numerous studies have examined its effects -- both helpful and harmful -- and scientists have taken out dozens of international patents for ibogaine therapeutic treatments.
"Most of those are based on studies of iboga use by Gabonese people, particularly by Bwiti practitioners," said Yann Guignon, from the Gabonese conservation group Blessings Of The Forest.
Despite the plant's "colossal therapeutic benefits", "Gabon is clearly missing out on the economic potential of iboga," he added.
"It did not position itself in this market in time by developing productive iboga plantations, a national processing laboratory and a proper industrial policy."
Overseas laboratories meanwhile have worked out how to make synthetic ibogaine and to extract it from other plants, such as Voacanga africana.
That flowering tree is available in greater quantities in Ghana and Mexico, which "can produce ibogaine at unbeatable prices", said Guignon.
And "Gabonese traditional knowledge is not protected by intellectual property regulations."
Currently only one company in Gabon has a licence to export iboga products -- though Minko, from the forestry ministry, said the country hopes this number will rise in the coming years.
She said companies were likely to produce more, spurred by revenue guarantees under the Nagoya Protocol, an international agreement on biological diversity and resource-sharing.
She wants the country to obtain a "made in Gabon" certificate of origin for iboga.
"This is a huge resource for Gabon. We have drawn up a national strategy for the conservation and sustainable use of the product," she said.
"Gatherings will soon be organised, bringing together all the groups concerned: NGOs, traditional practitioners and scientists."
Soothing properties
After harvesting iboga to the sound of traditional harps and consuming it in the initiation ceremony, Stephen Windsor-Clive was convinced by the benefits of iboga.
"I definitely want to bring my daughter here and have her have the experience," he said.
"This is my last attempt to find something which might be of assistance to her."
Another visitor, Tafara Kennedy Chinyere, travelled from Zimbabwe to discover Gabon and found, in the initiation, relief from anxiety and his "inner demons".
"I feel good in my body, in myself," he said, sitting under a tree after the ceremony.
"I feel like the iboga helped me to let go of things that you no longer need in your life."
© 2025 AFP
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Contraceptives destroyed in silence: 'Can France accept to become the executor of a senseless policy imposed by the US?'
Contraceptives destroyed in silence: 'Can France accept to become the executor of a senseless policy imposed by the US?'

LeMonde

timea day ago

  • LeMonde

Contraceptives destroyed in silence: 'Can France accept to become the executor of a senseless policy imposed by the US?'

A stockpile of several million doses of contraceptives, valued at $9.7 million, financed by USAID and usable until 2031, is currently being incinerated in France. These products, originally intended for women in extreme poverty in countries in the Global South, are being destroyed for purely ideological reasons, at the request of the Trump administration. The service provider tasked with the incineration has not yet been identified. This human and environmental waste must be stopped immediately. Why is this happening? Because the US administration, following a blinkered ideological agenda, ordered their destruction as part of the dismantling of USAID. It even refused to transfer the stock to NGOs who were ready to transport and distribute it. This is not a public health issue or a logistical problem. It is a radical political choice. USAID's logistics program, which is usually operated by the company Chemonics, appears to be linked to this operation. However, this cannot be confirmed, since neither the name of the logistics provider nor the name of the incinerator has been made public. The stock, which was previously stored in Belgium, was transported to France in about 10 trucks at the end of July. The exact location of the incineration is deliberately undisclosed. Despite the scale of the operation, the company responsible for handling the medical waste has not been identified. We contacted four major French waste management companies to ask whether they were involved in this operation. All replied that they were not concerned. An economic and environmental absurdity As NGOs active in several African countries, we know exactly what a contraceptive shortage means: unintended pregnancies, abandoned children, unsafe abortions, and girls forced out of school at age 12. It also means women trapped in unwanted motherhood. Can France accept to become the executor of a senseless policy imposed by the US without reaction? This destruction is also an economic and environmental absurdity. It costs more ($167,000) than it would to redistribute contraceptives to countries experiencing shortages. Eliminating usable products that are urgently needed in empty health centers will also generate metric tons of CO₂. It's a total waste.

Swiss regulator approves first malaria treatment for newborn babies
Swiss regulator approves first malaria treatment for newborn babies

Euronews

time08-07-2025

  • Euronews

Swiss regulator approves first malaria treatment for newborn babies

Switzerland's drug regulator has approved the world's first malaria treatment for newborn babies, clearing the way for the medicine to become available in parts of Africa where the life-threatening disease is endemic. In a late-stage clinical trial, pharmaceutical giant Novartis showed the drug was safe and effective for babies weighing less than five kilograms, which they typically reach by two months of age. Traditionally, these infants have been given either a full or half-dose of the antimalarial drug intended for babies six months or older. But because newborns do not process medicines the same way, there is a higher risk of side effects. The lack of specialised treatment – and the fact that babies are not vaccinated until they are around five months old – has left the youngest infants relatively unprotected against malaria, a mosquito-borne disease that kills about 597,000 people per year. Most deaths are among children under five years old in Africa. It's not clear exactly how many babies are affected, but in 2023, there were an estimated 36 million pregnancies in 33 African countries where malaria is widespread. About one in three mothers were infected with malaria while pregnant, raising the risk that they will pass the disease along to their newborns, according to the World Health Organization (WHO). 'Every one of those [babies] is a potential target for malaria infection,' Dr Lutz Hegemann, president of Novartis' global health programme, told Euronews Health. 'We don't want to leave any patient behind, no matter how small they are'. Eight African countries – Burkina Faso, Ivory Coast, Kenya, Malawi, Mozambique, Nigeria, Tanzania, and Uganda – are expected to quickly approve the medicine as part of a partnership with Swissmedic, the Swiss drugs regulator. Hegemann said Novartis hopes to roll the medicine out there this autumn, with more countries to follow, on a not-for-profit basis. The medicine, known as Coartem Baby, is similar to Novartis' existing drug to treat uncomplicated malaria in young children, but it has a different dose and ratio of ingredients to prevent side effects in the youngest infants. It also has a sweet cherry flavour and can be dissolved in breast milk to make it easier to give to patients. 'These are small changes, but big steps,' Dr Quique Bassat, head of the Barcelona Institute of Global Health, told Euronews Health. While the number of newborns with malaria 'still remains relatively modest in terms of the overall burden, those cases need to be treated, and therefore we need better drugs,' he added. 'Now we have something which is perfectly suitable for that specific age group where there was a gap'. Bassat advised Novartis on the clinical trial, which was funded by the European Union and the Swedish International Development Cooperation Agency.

Europe leads global vaccine effort as US pulls back
Europe leads global vaccine effort as US pulls back

Euronews

time26-06-2025

  • Euronews

Europe leads global vaccine effort as US pulls back

At a high-level pledging event in Brussels on Thursday, the GAVI Vaccine Alliance rallied international donors to fund its next five-year programme. So far, GAVI has secured over €7.7 billion – still short of its overall target, though more pledges are expected in the coming weeks. "What's at stake is the lives of millions and millions of children. And I think there is nothing more important in the world than the lives of millions of children," GAVI Chairman José Manuel Barroso told Euronews in an interview. 'It makes a difference if they get immunisation, if they get vaccines or not. Because if they don't get them, they will die from perfectly preventable diseases," he added. GAVI, launched in 2000, is a global health partnership aimed at improving vaccine access in the world's poorest countries. Since its inception, the alliance has helped vaccinate over one billion children and is estimated to have saved 19 million lives. Now, it aims to reach 500 million more by 2030. Supporters say vaccine investments offer a strong return – up to $54 for every dollar spent – through reduced healthcare costs and increased economic productivity. Europe Leads the Charge European nations were among the most prominent backers at the Brussels event. Spain's Prime Minister Pedro Sánchez pledged €130 million, 30% more than the country's previous commitment. 'Spain is ready to take a step forward when others are backing down,' he said. The European Commission also reaffirmed its support with a €360 million pledge, bringing the total 'Team Europe' commitment — combining EU institutions and member states — to more than €2 billion. Commission President Ursula von der Leyen welcomed GAVI and UNICEF's commitment to procure up to 20% of vaccines in their programmes from African producers. 'Together we can ensure that vaccines are not only available to Africa, but increasingly made in Africa,' she said at the event, mentioning that Europe is also the largest contributor to the Africa vaccine manufacturing accelerator. The United Kingdom emerged as the single largest donor, committing £1.25 billion. 'Where others are stepping back, we in the United Kingdom are stepping up,' said UK Foreign Secretary David Lammy. 'This will help immunise over 60 million children, saving an estimated 1.25 million lives.' United States pulls out In a stark contrast to past years, the United States — historically a major donor to GAVI — announced it would no longer provide funding, as part of a broader reduction in international aid under President Donald Trump's administration. 'There is much I admire about GAVI,' said US Health Secretary Robert F. Kennedy Jr. in a video message. 'Unfortunately, in its zeal to promote universal vaccination, it has neglected the key issue of vaccine safety.' Kennedy, a known vaccine sceptic, specifically raised concerns about the DTP vaccine (diphtheria, tetanus, and pertussis), a widely used childhood immunisation. GAVI responded by reaffirming its "full confidence" in the DTP vaccine, citing decades of rigorous safety monitoring. Barroso, in a separate interview prior to Kennedy's statement, maintained an optimistic tone about future collaboration with the US administration. However, he also denounced vaccine disinformation campaigns fuelled by conspiracy theories and social media. 'People, sometimes, like to accept these kinds of fantasies,' he said. As Barroso concluded, the global data on vaccination impact is indisputable: countries with sustained immunisation programmes have seen drastically lower child mortality rates. Preventable diseases like polio, once widespread, have nearly disappeared in these regions. "Vaccines save lives and that's hard evidence," he said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store